Fu LY, Zhang HB. Effective treatment of polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes syndrome with congestive heart failure: A case report. World J Clin Cases 2021; 9(25): 7504-7511 [PMID: 34616819 DOI: 10.12998/wjcc.v9.i25.7504]
Corresponding Author of This Article
Hong-Bin Zhang, MD, Chief Physician, Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing 400016, China. usamake@163.com
Research Domain of This Article
Hematology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Sep 6, 2021; 9(25): 7504-7511 Published online Sep 6, 2021. doi: 10.12998/wjcc.v9.i25.7504
Effective treatment of polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes syndrome with congestive heart failure: A case report
Ling-Yao Fu, Hong-Bin Zhang
Ling-Yao Fu, Hong-Bin Zhang, Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
Author contributions: Fu LY prepared and reviewed the manuscript; Zhang HB supervised the work; all authors read and approved the final manuscript.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: Hong-Bin Zhang is an employee of The First Affiliated Hospital of Chongqing Medical University.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hong-Bin Zhang, MD, Chief Physician, Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing 400016, China. usamake@163.com
Received: March 8, 2021 Peer-review started: March 8, 2021 First decision: March 25, 2021 Revised: April 5, 2021 Accepted: July 14, 2021 Article in press: July 14, 2021 Published online: September 6, 2021 Processing time: 175 Days and 22.4 Hours
Core Tip
Core Tip: The standardized treatment for multiple myeloma may become the first reference for the treatment of polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome. We believe that the treatment effect for POEMS syndrome is poor once heart failure occurs. Therefore, early identification of heart disease and its cause along with timely follow-up treatment are critical to the treatment of POEMS syndrome. Whether this patient continues to undergo peripheral blood stem cell transplantation treatment after drug treatment remains to be evaluated. To date, the surgical indications and results have not been well defined, and a method for preventing heart disease has not been established for POEMS patients without heart failure.
